



ELSEVIER

Contents lists available at ScienceDirect

IJP: Drugs and Drug Resistance

journal homepage: www.elsevier.com/locate/ijpddr

Evaluation of synergy between host and pathogen-directed therapies against intracellular *Leishmania donovani*

M. Shamim Hasan Zahid^a, Monica M. Johnson^a, Robert J. Tokarski II^c, Abhay R. Satoskar^b, James R. Fuchs^c, Eric M. Bachtelder^a, Kristy M. Ainslie^{a,d,*}

^a Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA

^b Department of Pathology, Medical Center, The Ohio State University, Columbus, OH, 43210, USA

^c Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA

^d Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA

ARTICLE INFO

Keywords:

Visceral leishmaniasis
Resazurin assay
Host-directed therapy
Combinatorial therapy
AR-12
DNER-4

ABSTRACT

Visceral leishmaniasis (VL) is associated with treatment complications due to the continued growth of resistant parasites toward currently available pathogen-directed therapeutics. To limit the emergence and combat resistant parasites there is a need to develop new anti-leishmanial drugs and alternative treatment approaches, such as host-directed therapeutics (HDTs). Discovery of new anti-leishmanial drugs including HDTs requires suitable *in vitro* assay systems. Herein, we modified and evaluated a series of resazurin assays against different life-stages of the VL causing parasite, *Leishmania donovani* to identify novel HDTs. We further analyzed the synergy of combinatorial interactions between traditionally used pathogen-directed drugs and HDTs for clearance of intracellular *L. donovani*. The inhibitory concentration at 50% (IC₅₀) of the five evaluated therapies [amphotericin B (AMB), miltefosine, paromomycin, DNER-4, and AR-12 (OSU-03012)] was determined against promastigotes, extracellular amastigotes, and intracellular amastigotes of *L. donovani* via a resazurin-based assay and compared to image-based microscopy. Using the resazurin-based assay, all evaluated therapies showed reproducible anti-leishmanial activity against the parasite's different life-stages. These results were consistent to the traditional image-based technique. The gold standard of therapy, AMB, showed the highest potency against intracellular *L. donovani*, and was further evaluated for combinatorial effects with the HDTs. Among the combinations analyzed, pathogen-directed AMB and host-directed AR-12 showed a synergistic reduction of intracellular *L. donovani* compared to individual treatments. The modified resazurin assay used in this study demonstrated a useful technique to measure new anti-leishmanial drugs against both intracellular and extracellular parasites. The synergistic interactions between pathogen-directed AMB and host-directed AR-12 showed a great promise to combat VL, with the potential to reduce the emergence of drug-resistant strains.

1. Introduction

Leishmaniasis is a life-threatening neglected tropical disease caused by obligate intracellular parasites of the genus *Leishmania* and approximately a tenth of the world is at risk of infection (World Health Organization, 2018; Zulfiqar et al., 2017). The disease is broadly classified as either a cutaneous (CL) or visceral leishmaniasis (VL), the latter being the disease's most fatal form and is mainly caused by two species (of 29 species): *Leishmania donovani* (*L. donovani*) and *L. infantum*. Globally, ~90,000 new cases of VL are reported each year, with an approximately 95% fatality rate if left untreated (World Health Organization, 2018; Zulfiqar et al., 2017).

A vaccine against *Leishmania* has not yet been developed and current first-line therapies include amphotericin B (AMB), miltefosine, paromomycin, and antimonials [e.g., sodium stibogluconate (SSG)] (Palatnik-de-Sousa, 2008). These therapies have adverse side effects, often require long treatment regimens, and act directly on the pathogen, imposing an increased risk of developing drug resistance (Croft et al., 2006; Freitas-Junior et al., 2012; Sundar and Chakravarty, 2010). Drug resistance was presented in more than 60% of clinical isolates in the Bihar region of India, with reported resistance to SSG (Rijal et al., 2003), and AMB (Purkait et al., 2012). For example, the parasite *Leishmania* are prone to acquiring resistance to miltefosine due to its elongated drug half-life (~150 h), long treatment course (~28 days),

* Corresponding author. 125 Mason Farm Road, 4211 Marsico Hall, CB, #7362, Chapel Hill, NC, 27599, USA.

E-mail address: ainsliek@email.unc.edu (K.M. Ainslie).

<https://doi.org/10.1016/j.ijpddr.2019.08.004>

Received 30 May 2019; Received in revised form 16 August 2019; Accepted 21 August 2019

Available online 21 August 2019

2211-3207/© 2019 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).




Fig. 1. Resazurin assay to measure *L. donovani* (A) promastigote and (B) amastigote viability. Correlation between Relative Fluorescence Units (RFUs) production with different parasite numbers were highly significant ($p < 0.005$) as determined by Pearson's r-analysis ($r > 0.94$ for promastigotes, and $r > 0.99$ for amastigotes). This is a representative data of two biological repeats, which is reported as mean \pm standard deviation (SD) of triplicate samples and with background subtracted.




Fig. 2. Direct effects of drugs on (A) extracellular promastigotes and (B) axenic amastigotes, via resazurin assay. Data (mean \pm SD) are normalized to non-treated control groups. Assays ran in triplicate with two biological repeats.

Table 1

Anti-leishmanial drugs against extracellular promastigotes, amastigotes, and intracellular amastigotes. All assays were run in triplicate and data (means \pm SD) from two biological repeats. IC₅₀: Inhibitory Concentration at 50%; LD₅₀: 50% Lethal Dose for BMDMs. *, significant lower IC₅₀ of drugs against intracellular amastigotes compared to extracellular promastigotes of the respective group (** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$).#, significant lower IC₅₀ of drugs against intracellular amastigotes compared to axenic amastigotes of the respective group (### $p < 0.001$).‡, significant lower IC₅₀ of drugs against axenic amastigotes compared to extracellular promastigotes of the respective group (‡ $p < 0.01$, ‡‡ $p < 0.001$). A one-way ANOVA (Tukey's multiple comparisons test) was conducted comparing effects of the drugs on different life-stages of the parasites.

Compounds	IC ₅₀ (μM) for <i>L. donovani</i>			Cytotoxicity LD ₅₀ (μM)	
	Extracellular promastigotes	Axenic amastigotes	Intracellular amastigotes		
			Image based assay	Resazurin assay	
Amphotericin B	0.047 \pm 0.004	0.049 \pm 0.005	0.024 \pm 0.001	0.033 \pm 0.011	38.5 \pm 4.95
Miltefosine	5.4 \pm 0.42	2.13 \pm 0.53‡	1.1 \pm 0.37	0.55 \pm 0.15****/###	62.5 \pm 4.95
Paromomycin	59 \pm 5.66	22 \pm 4.24‡‡	15.2 \pm 4.67	11.6 \pm 0.42****	> 800
DNER-4	5.82 \pm 1.10	4.45 \pm 0.21	5.2 \pm 2.55	3.2 \pm 0.28**	78.5 \pm 9.2
AR-12	3.3 \pm 0.42	3.45 \pm 0.07	1.18 \pm 0.18	1.44 \pm 0.08****/###	11.1 \pm 2.5

and parasite susceptibility to develop a single point mutation (Mishra and Singh, 2013; Perez-Victoria et al., 2006; Seifert et al., 2007).

New approaches to traditional monotherapies are needed to combat drug resistance. Combinatorial therapies could decrease monotherapy duration and dosage, leading to reduced resistance (Sundar and Chakravarty, 2013). A reduced treatment duration was observed in a clinical trial using paromomycin and SSG to cure VL. The treatment duration went from 30 days with monotherapy to 17 days with combination (Musa et al., 2012). In another clinical study, a single dose of liposomal AMB (AmBisome) with 7-days of miltefosine cured 98% of the VL patients, compared to 91% with AMB alone (Sundar et al., 2008). However, there is no evidence suggesting that combinatorial

effects of two primarily pathogen-mediated drugs mitigates drug-resistance.

In addition to combined therapies, host-directed therapies (HDTs) may better target the host's response to the pathogen as opposed to just the pathogen directly, which could lead to reduced emergence of resistance (Collier et al., 2013). Often HDTs' mechanism is to modulate the host's immune response through induction of pro-inflammatory cytokines (e.g., IFN- γ , IL-12). In particular, IFN- γ has been shown to be essential in treating leishmaniasis (Wang et al., 1994). Combination treatment with pentavalent antimonials and recombinant IFN- γ increased the VL cure rate compared to individual treatment alone (Squires et al., 1993; Sundar et al., 1997). Similarly, sub-optimal doses




Fig. 3. (A) Macrophage cytotoxicity, and intracellular parasite burden in presence of drugs (normalized to untreated), determined by (B) the modified resazurin assay and (C) the traditional microscopic image-based assay. Data is presented as means \pm SD, ran in triplicate with two biological replicates.

of AMB with IL-12 cleared VL compared to higher dosing of AMB alone (Murray et al., 2003). Although promising, the high cost of recombinant protein and required cold-chain storage reduces the feasibility of cytokine therapies in developing nations.

There are a few small molecule HDTs to treat *Leishmania* currently in the development pipeline, and they may work synergistically in combination with pathogen-directed therapies (i.e., AMB, miltefosine). Celecoxib, a Cyclooxygenase-2 (COX-2) inhibitor, has been shown to suppress tumor cell viability through disruption of PDK-1/Akt signaling and induction of apoptosis (Kucab et al., 2005; Zhou et al., 2018). Our laboratory has evaluated AR-12 (OSU-03012), an IND-approved derivative of celecoxib that lacks COX-2 inhibitor activity, as a novel HDT against intracellular *L. donovani* (Collier et al., 2016). In addition, AR-12 has been reported to induce host-mediated reduction of *Salmonella enterica* (Chiu et al., 2009a; Hoang et al., 2014), *Francisella tularensis* (Hoang et al., 2016), *F. novicida* (Chiu et al., 2009b), and *Cryptococcus neoformans* (Baxter et al., 2011). Although promising, AR-12's hydrophobicity makes it difficult to deliver at therapeutic levels. To deliver it better, we have encapsulated AR-12 within biodegradable acetalated dextran (Ace-DEx) microparticles (AR-12/MPs), which can passively target phagocytic host cells for site-specific drug delivery (Collier et al., 2016; Hoang et al., 2014, 2016). We have previously shown that treatment with AR-12/MPs significantly reduced hepatic, splenic, and bone marrow *L. donovani* loads in infected mice compared to free AR-12 (Collier et al., 2016).

In addition to AR-12, our group has aided in discovery of anti-leishmanial compounds isolated from the roots of *Pentalinon andrieuxii*, including pentalinonsterol (PEN) and 6,7-dihydroneridienone (DNER), both of which have host-mediated as well as pathogen-directed activity. Although not fully elucidated, as derivatives of plant sterols, both PEN and DNER could interfere with the sterol biosynthesis pathway (Pan et al., 2012). Suboptimal doses of DNER has anti-leishmanial activity ($IC_{50} = 1.4 \mu M$) against intracellular *L. mexicana*, in addition to direct activity against promastigotes at higher concentrations ($IC_{50} = 9.2 \mu M$) (Pan et al., 2012). Herein, we are evaluating the effects of a DNER analog, DNER-4, against *L. donovani*.

The discovery of new anti-leishmanial compounds largely depends

on a simple, cheap, and reproducible assay system; however, they are often difficult to develop because the parasite has a complex life-cycle, requiring drug screening against promastigotes, and extracellular and intracellular amastigotes (Callahan et al., 1997; Kamhawi, 2006; Kiderlen and Kaye, 1990; Mikus and Steverding, 2000). For evaluation of intracellular amastigotes, labor-intensive microscopy-based direct counting of cells and parasites is considered the gold-standard (Neal and Croft, 1984). For both life-stages, reporter gene based automated screening is also not ideal as most assays require drug selection for maintaining the optimal reporter gene expression, which could directly interfere with the anti-infective efficacy, increasing false positives (Mandal et al., 2009). Moreover, there are issues of sensitivity and background in some reporter gene-based assays as they often cannot differentiate live and dead intracellular amastigotes (Gupta, 2011; Sereno et al., 2007). A resazurin based assay could be better because a metabolically active parasite is required to form fluorescent resorufin, and it can be analyzed in a throughput manner irrespective of a genetically modified parasites, which can facilitate use of clinical isolates (Paape et al., 2014). However, due to potential host cell interference, resazurin-based anti-leishmanial drug screening in an intracellular system requires some modifications. This article modifies and evaluates a resazurin based drug screening assay using different *L. donovani* life-stages to identify new anti-leishmanial combination therapies of conventional pathogen-directed drugs and host-directed compounds (AR-12 and DNER-4).

2. Materials and methods

2.1. Chemicals and reagents

All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless indicated otherwise. AR-12 was purchased from GenDEPOT (Katy, TX). DNER-4 is an analog of plant sterol DNER derived from cholic acid. The synthetic procedures for the preparation of DNER-4 and associated characterization data are included in the Supplementary Information (SI) file.




Fig. 4. Intracellular anti-leishmanial efficacy (normalized to untreated infected control) of amphotericin B (AMB) in combination with other drugs: (A) miltefosine, (B) paromomycin, (C) DNER-4, and (D) AR-12 via resazurin assay. Data is presented as means \pm SD, ran in triplicate with two biological replicates.

2.2. Compound mammalian cytotoxicity determination

Mouse bone marrow-derived macrophages (BMDMs) isolation from BALB/c mice and culture was done as described previously (Weischenfeldt and Porse, 2008), and approved by the Animal Care and Use Committees at UNC. A lactate dehydrogenase (LDH) assay (Thermo Fisher Scientific, Grand Island, NY) was used to determine cytotoxicity per manufacturer's directions. Control wells had DMEM or DMEM containing 0.1% dimethyl sulfoxide (DMSO).

2.3. Resazurin-based drug susceptibility assay on promastigotes and axenic amastigotes

Leishmania donovani strain (ATCC 30030; ATCC; Manassas VA) was used in all studies and grown via manufacture's specification. The promastigotes screening were performed as described previously, with few modifications (Kulshrestha et al., 2013). Late log-phase promastigotes (1×10^5 per one 96-well) were incubated with drug for 72 h at 25 °C. Resazurin was added [0.002% (w/v)], incubated for 24 h and assessed fluorometrically (ex: 544 nm/em: 590 nm; SpectraMax M2, Molecular Devices, Sunnyvale, CA). *L. donovani* axenic amastigotes were differentiated as described previously, with little modification (Ephros et al., 1997). Late log-phase promastigotes were differentiated into axenic amastigotes in a low pH (6.3) medium for 96 h at 37 °C. Fully differentiated axenic amastigotes (2×10^5 per one 96-well) were incubated 72 h with drug at 37 °C, and resazurin assay was then

performed as indicated above. The parasite's Inhibitory Concentration 50% (IC₅₀) was determined from a best fit trend-line of two experimental repeats.

2.4. Image-based evaluation of intracellular anti-leishmanial activity

An image-based anti-leishmanial assay was used as described previously with slight modification (Collier et al., 2016). BMDMs seeded on round glass coverslips (5×10^5 cells per one 24-well) were allowed to adhere overnight, infected with stationary phase *L. donovani* promastigotes (MOI 1:10), incubated overnight, and washed ($3 \times$) with warmed serum-free media. Compounds were added, incubated for 72 h, washed ($3 \times$) with PBS, fixed with methanol and stained with Giemsa stain (1:20 in H₂O). An EVOS XL (100 \times , Thermo Fisher Scientific) was used for imaging. *L. donovani* amastigotes per 100 macrophages was determined, in duplicate, and in a blinded fashion.

2.5. Resazurin-based viability analysis of *L. donovani* in infected macrophages

BMDMs (1×10^5 per one 96-well) infected overnight with stationary phase *L. donovani* promastigotes (MOI 1:10), were washed ($3 \times$) with serum free DMEM, and incubated with compounds for 72 h. Then, parasites were rescued with BMDM controlled lysis, modified from a previous report (Kiderlen and Kaye, 1990). In brief, cells were washed with serum-free HEPES-buffered RPMI (HEPES-RPMI; 1 \times), lysed




Fig. 5. Isobolograms demonstrating combinatorial effects of amphotericin B (AMB) with other anti-leishmanial drugs (normalized to untreated controls): (A) miltefosine, (B) paromomycin, (C) DNER-4, and (D) AR-12 via resazurin assay. A combination index (CI) = 1 of drugs represented additivity line, and the error range of additivity is accompanied with a clear window. CI values above the error range of additivity line (in the dark grey shaded region) represented antagonistic effects (CI > 1) between drugs, and points below the error range of the additivity line reflected synergistic effects (CI < 1, light grey).

Table 2
Combination index (CI) for the synergistic effects of AMB and AR-12. Data were performed in triplicate and reported as mean.

AR-12 (µM)	Resazurin assay		Image-based assay	
	IC ₅₀ of AMB (µM)	CI	IC ₅₀ of AMB (µM)	CI
0	0.033	–	0.024	–
0.1	0.022	0.96	0.018	0.85
0.2	0.013	0.70	0.014	0.79
0.3	0.008	0.62	0.007	0.56
0.4	0.006	0.66	0.006	0.62
0.5	0.008	0.84	0.005	0.68

(20 min) with HEPES-RPMI (100 µL/well) with 0.008% SDS (w/v), SDS neutralized with HEPES-RPMI with 17% FBS (v/v; 150 µL/well) and placed in an air-tight container (25 °C for 96 h). Resazurin [0.02% (w/

v); 25 µL] was added, incubated (24 h) and was assessed fluorometrically.

2.6. Determination of intracellular anti-leishmanial synergy

The combination index (CI) for each of the combinations of the drugs was determined by using the Chou et al. method using Eqn (1):

$$CI = \frac{C_A}{IC_{50A}} + \frac{C_B}{IC_{50B}} \tag{1}$$

where C_A and C_B are the concentrations of the corresponding drugs, and IC_{50A} and IC_{50B} are the IC₅₀ values of the drugs when administrated alone (Chou and Talalay, 1984).




Fig. 6. Combinatorial effects were determined by traditional Giemsa stain-based image assay. (A) Anti-leishmanial effects of AMB and AR-12. (B) Isobologram showing combinatorial interactions between AMB and AR-12.

3. Results and discussion

3.1. Validation of resazurin assay for anti-leishmanial drug screening

Resazurin, a blue non-fluorescent and non-toxic dye is irreversibly reduced to a pink, highly fluorescent resorufin by mitochondrial dehydrogenase enzymes within metabolically active cells (Shahangian et al., 1984). Although resorufin can be further reduced to non-fluorescent dihydroresorufin, a linear increase of fluorescent signal was observed with viable *Leishmania* parasites over a period of 72 h, demonstrating the stability of resorufin-mediated signal (Paape et al., 2014). In addition to its utility in confirming microbiological contamination in milk, resazurin-based reduction assay is widely used to analyze chemical cytotoxicity and minimum inhibitory concentration values for antimicrobial agents (Hudman and Sargentini, 2013; McNicholl et al., 2007; O'Brien et al., 2000; Sarker et al., 2007). We have evaluated resazurin-based anti-leishmanial drug screening assay on different life-stages of parasite because it is simple, cost-effective, reproducible and requires a viable parasite. This assay is relatively inexpensive (~\$13/gram of resazurin) and can be used in a throughput screening manner with wild-type strains. Other screening assay, such as fluorescent-based reporter genes and monoclonal antibodies for flow cytometry are less sensitive and have limitations for longer drug treatment duration (Abdullah et al., 1999). Additionally, reporter gene-based screening requires genetically modified parasites, limiting evaluation against clinical strains (Mandal et al., 2009). Moreover, fluorescent markers can have a high background due to auto-fluorescence of host cells and cannot distinguish between live and dead intracellular amastigotes, which affects both the reproducibility and sensitivity of these assays (Gupta, 2011; Sereno et al., 2007). Fig. 1 reports the validation of resazurin assay with extracellular promastigotes and amastigotes (Kulshrestha et al., 2013; Paape et al., 2014) by confirming an increase in parasite number with Relative Fluorescence Units (RFUs). A direct significant linear correlation ($p < 0.005$) between conversion of resazurin to RFUs with increasing parasite numbers were observed in Pearson's r-analysis ($r > 0.94$). Moreover, promastigote and amastigote viability testing with resazurin is highly reproducible, and required 10^3 viable *Leishmania* parasites to generate a detectable fluorescent signal in our experimental set up (Fig. S1). On the contrary, dead *Leishmania* parasites (treated with 10% SDS for 20 min to ensure complete death) did not produce greater fluorescent signal compared to media background (data not shown) demonstrated resazurin assay is highly sensitive to detect viable parasites.

For anti-leishmanial drug screening, promastigote viability is often used, but it is not always reproducible in an intracellular infection model (De Muylder et al., 2011). Axenic amastigotes may better replicate intracellular models (Sereno and Lemesre, 1997). Herein, known and potential anti-leishmanial compounds were evaluated against promastigotes and axenic amastigotes using a resazurin assay (Fig. 2, Table 1). Among the current therapies, AMB was the most potent against both promastigotes (IC_{50} 0.047 μ M) and axenic amastigotes (IC_{50} 0.049 μ M) with miltefosine and paromomycin as the most effective against agent axenic amastigotes. The IC_{50} s of AR-12 and DNER-4 did not vary much across promastigote (3.3 and 5.82 μ M, respectively) and axenic amastigote (3.45 and 4.45 μ M, respectively) stages.

There are significant differences that exist between intracellular amastigotes and axenic amastigotes in protein expression and drug susceptibility (Holzer et al., 2006; Pescher et al., 2011). Spleen-derived hamster *L. donovani* amastigotes were more infective and pathogenic compared to axenically grown amastigotes due to overexpression of virulence associated proteins (Iyer et al., 2008; Pescher et al., 2011). In another study, anti-leishmanial activity of naloxonazine was found only against intracellular *L. donovani* amastigotes but not on axenically grown amastigotes (De Muylder et al., 2011). These studies highlight the importance of evaluating anti-leishmanial drugs against promastigotes, axenic amastigotes and intracellular amastigotes and therefore

drugs were screened against intracellular amastigotes using the modified resazurin assay.

The relative cytotoxicity of the evaluated compounds was analyzed on mouse BMDMs (Fig. 3A, Tables 1 and S1). Using a non-toxic dosing range, the modified resazurin-based method was used for determination of intracellular anti-leishmanial activity (Table 1, Fig. 3B). These results were comparable to the traditionally used microscopic technique (Table 1, Figs. 3C and S2), suggesting that the modified resazurin assay can be used in place of labor-intensive, microscopy-based direct counting method.

The IC_{50} s of AMB did not differ much across extracellular promastigote (0.047 μ M), axenic amastigote (0.049 μ M) and intracellular amastigotes (0.033 μ M), as previously reported (Paape et al., 2014). However, miltefosine and paromomycin showed greater intracellular anti-leishmanial activity compared to extracellular anti-infectivity, indicating potential host-directed activity (Table 1). Miltefosine not only acts directly on the cell membrane of *Leishmania*, but it can also induce IFN- γ receptor activity in *L. donovani*-infected macrophages, which might contribute to the host-directed effects (Wadhone et al., 2009). The intracellular anti-leishmanial activity of HDT AR-12 presented here (Fig. 3, Table 1) corresponds with our published work where the IC_{50} of extracellular promastigotes and amastigotes (3.3 and 3.45 μ M, respectively) are significantly higher than intracellular concentrations (1.44 μ M), supporting a host-mediated mechanism (Collier et al., 2016). Although not fully elucidated, AR-12 mediated inhibition of Akt kinase signaling could modulate *Leishmania* inducing Akt signaling to confer host cell resistance to apoptosis (Kucab et al., 2005; Neves et al., 2010; Ruhland et al., 2007). Hence, it is possible that AR-12 may interfere with the parasite-mediated induction of Akt signaling. Future work will aim to identify the mechanism of AR-12 mediated clearance of intracellular *L. donovani*.

DNER-4 also showed potential direct activity on extracellular promastigotes and amastigotes (5.82 and 4.45 μ M, respectively) (Table 1); however, it was more potent against the intracellular parasite (3.2 μ M), indicating a preference in host-directed activity. Although not fully elucidated, DNER-4 could interfere with the sterol biosynthesis pathway of *Leishmania*, which would disrupt the normal structure and function of parasites (de Souza and Rodrigues, 2009; Pan et al., 2012). On the other hand, several phytosterols, such as sitosterol can induce IFN- γ production in human peripheral blood mononuclear cells (Brull et al., 2010). Thus, as a derivative of a plant sterol, DNER-4 could induce IFN- γ production in mouse BMDMs to attribute to its host-directed leishmanicidal activity. However, further studies are warranted to confirm these hypotheses.

3.2. Combinatorial host-directed leishmanicidal activities of anti-leishmanial drugs

We aimed to evaluate the combination therapy of two anti-leishmanial drugs utilizing the modified resazurin assays. Irrespective of the parasitic life-stages, AMB was the most potent (i.e., lowest IC_{50}) among the tested compounds (Table 1). A combinatorial assay was performed varying AMB concentration at fixed and sub-optimal concentrations of other compounds (Fig. 4). Normalized parasite viability with comparison to untreated controls was calculated for individual drugs as well as for their combinations. However, to better highlight the synergistic effects of the combination therapies depicted in Fig. 4, isobolograms were generated for each of the combinations (Fig. 5). The combination index (CI) was determined for each of the combinations of the drugs by using Eqn (1). As shown in Fig. 5, the additivity line (CI = 1) is accompanied with a clear window represents the error range of additivity. Thus, points above the additivity line (CI > 1, dark grey) are antagonistic, and those below the line (CI < 1, light grey) are synergistic.

AMB and miltefosine demonstrated mild synergistic effects (Fig. 5A), although it has been previously reported that the anti-leishmanial activity of miltefosine was greatly enhanced in combination

with AMB *in vivo* (Seifert and Croft, 2006). As shown in Fig. 5B, paromomycin in combination with AMB showed additive anti-leishmanial interactions at relatively lower doses, however, at higher concentrations, antagonism was observed. Although primarily pathogen-directed therapies like AMB, miltefosine, and paromomycin can effectively cure VL, it is unlikely that these drugs (either individual or in combination) could mitigate the emergence of drug-resistant strains.

To further improve the current combinatorial approach to treat VL, we analyzed the combinatorial effects between a pathogen-directed and a HDT. Therefore, we tested the effects of DNER-4, a potential HDT, in combination with AMB against intracellular *L. donovani*. As outlined in Fig. 5C, a strong antagonistic effect was observed when combined with AMB. This antagonistic response could be due to the affinity of AMB for sterols or sterol derivatives like DNER-4 (Pan et al., 2012; Urbina et al., 1987). It can be hypothesized that AMB interacts with DNER-4, diminishing the leishmanicidal properties of both drugs in a combined therapy. These results highlight the importance of evaluating the chemical properties and mechanisms of action of individual drugs when selecting for a combination therapy.

Next, we evaluated the combinatorial effects of the host-directed drug AR-12 with AMB to eradicate intracellular *Leishmania*. Herein, we demonstrate that a synergistic effect, indicative of $CI < 1$, was observed when variable suboptimal concentrations of AMB in combination with suboptimal doses of AR-12, compared to AMB treatment alone (Fig. 5D and Table 2). These results were confirmed using the traditional image-based counting of amastigotes around BMDM nuclei (Fig. S3). Image-based evaluation of reduced parasite viability (Fig. 6A) and synergistic CI values (Fig. 6B) with combinatorial treatment of suboptimal doses of AMB and AR-12 compared to either treatment alone further demonstrated the anti-leishmanial efficacy of this combination (Table 2).

Synergistic intracellular leishmanicidal interaction between pathogen-directed AMB and host-directed AR-12 showed great promise to treat VL. To truly evaluate the effects of synergistic pathogen and host-directed therapies, additional studies will need to be performed to evaluate both *in vitro* and *in vivo* synergistic anti-leishmanial interactions of AMB and AR-12 on a drug resistant *L. donovani*. However, prior to evaluating this therapy *in vivo*, limitations of toxicity and hydrophobicity of the two drugs needs to be addressed. For AR-12, these concerns can be mitigated by formulating AR-12 into biodegradable Ace-DEX microparticles (Ace-DEX MPs), as we showed previously (Collier et al., 2016). Additionally, encapsulation of AMB in a liposome (Ambisome) has been shown to mitigate toxicity (Adler-Moore and Proffitt, 2002). It would be pertinent to investigate such formulations to further develop these therapies to treat *L. donovani* infections *in vivo*.

4. Conclusions

We have modified and evaluated resazurin-based assays on different life-stages of *Leishmania*, which will facilitate *in vitro* screening of new anti-leishmanial therapies, particularly HDTs. Modified resazurin assay for anti-leishmanial drug screening on clinically relevant intracellular amastigotes is simple, inexpensive, reproducible, and comparable to the traditional microscopy-based image assay. Also, the synergistic interactions between pathogen-directed AMB and host-directed AR-12 to clear intracellular *L. donovani* shows great promise to combat VL, particularly in view of growing resistance to available therapies. Overall, this study provides sustained efforts to enrich current pipeline of anti-leishmanial drugs and contributes to improve or modify the current therapeutic approaches to combat VL.

Funding

This study was supported by the National Institutes of Health (NIH), United States (5R21AI123692).

Conflicts of interest

None to declare.

Acknowledgements

We are thankful to Erica N. Pino and Dr. Elizabeth Graham-Gurysh (Eshelman School of Pharmacy, University of North Carolina at Chapel Hill) for helpful discussions.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ijpddr.2019.08.004>.

References

- Abdullah, S.M., Flath, B., Presber, H.W., 1999. Comparison of different staining procedures for the flow cytometric analysis of U-937 cells infected with different *Leishmania*-species. *J. Microbiol. Methods* 37, 123–138.
- Adler-Moore, J., Proffitt, R.T., 2002. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. *J. Antimicrob. Chemother.* 49 (Suppl. 1), 21–30.
- Baxter, B.K., DiDone, L., Ogu, D., Schor, S., Krysan, D.J., 2011. Identification, *in vitro* activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules. *ACS Chem. Biol.* 6, 502–510.
- Brull, F., Mensink, R.P., van den Hurk, K., Duijvestijn, A., Plat, J., 2010. TLR2 activation is essential to induce a Th1 shift in human peripheral blood mononuclear cells by plant stanols and plant sterols. *J. Biol. Chem.* 285, 2951–2958.
- Callahan, H.L., Portal, A.C., Devereaux, R., Grogl, M., 1997. An axenic amastigote system for drug screening. *Antimicrob. Agents Chemother.* 41, 818–822.
- Chiu, H.C., Kulp, S.K., Soni, S., Wang, D., Gunn, J.S., Schlesinger, L.S., Chen, C.S., 2009a. Eradication of intracellular *Salmonella enterica* serovar Typhimurium with a small-molecule, host cell-directed agent. *Antimicrob. Agents Chemother.* 53, 5236–5244.
- Chiu, H.C., Soni, S., Kulp, S.K., Curry, H., Wang, D., Gunn, J.S., Schlesinger, L.S., Chen, C.S., 2009b. Eradication of intracellular *Francisella tularensis* in THP-1 human macrophages with a novel autophagy inducing agent. *J. Biomed. Sci.* 16, 110.
- Chou, T.C., Talalay, P., 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv. Enzym. Regul.* 22, 27–55.
- Collier, M.A., Gallovic, M.D., Peine, K.J., Duong, A.D., Bachelder, E.M., Gunn, J.S., Schlesinger, L.S., Ainslie, K.M., 2013. Delivery of host cell-directed therapeutics for intracellular pathogen clearance. *Expert Rev. Anti Infect. Ther.* 11, 1225–1235.
- Collier, M.A., Peine, K.J., Gautam, S., Oghumu, S., Varikuti, S., Borteh, H., Papenfuss, T.L., Sataoskar, A.R., Bachelder, E.M., Ainslie, K.M., 2016. Host-mediated *Leishmania donovani* treatment using AR-12 encapsulated in acetalated dextran microparticles. *Int. J. Pharm.* 499, 186–194.
- Croft, S.L., Sundar, S., Fairlamb, A.H., 2006. Drug resistance in leishmaniasis. *Clin. Microbiol. Rev.* 19, 111–126.
- De Muylder, G., Ang, K.K., Chen, S., Arkin, M.R., Engel, J.C., McKerrow, J.H., 2011. A screen against *Leishmania* intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. *PLoS Neglected Trop. Dis.* 5, e1253.
- de Souza, W., Rodrigues, J.C., 2009. Sterol biosynthesis pathway as target for anti-trypanosomatid drugs. *Interdiscip. Perspect. Infect. Dis.* 2009, 642502.
- Ephros, M., Waldman, E., Zilberstein, D., 1997. Pentostam induces resistance to antimony and the preservative chlorocresol in *Leishmania donovani* promastigotes and axenically grown amastigotes. *Antimicrob. Agents Chemother.* 41, 1064–1068.
- Freitas-Junior, L.H., Chatelain, E., Kim, H.A., Siqueira-Neto, J.L., 2012. Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? *Int. J. Parasitol. Drugs Drug Resist.* 2, 11–19.
- Gupta, S., 2011. Visceral leishmaniasis: experimental models for drug discovery. *Indian J. Med. Res.* 133, 27–39.
- Hoang, K.V., Borteh, H.M., Rajaram, M.V., Peine, K.J., Curry, H., Collier, M.A., Homsy, M.L., Bachelder, E.M., Gunn, J.S., Schlesinger, L.S., Ainslie, K.M., 2014. Acetalated dextran encapsulated AR-12 as a host-directed therapy to control *Salmonella* infection. *Int. J. Pharm.* 477, 334–343.
- Hoang, K.V., Curry, H., Collier, M.A., Borteh, H., Bachelder, E.M., Schlesinger, L.S., Gunn, J.S., Ainslie, K.M., 2016. Needle-free delivery of acetalated dextran-encapsulated AR-12 protects mice from *Francisella tularensis* lethal challenge. *Antimicrob. Agents Chemother.* 60, 2052–2062.
- Holzer, T.R., McMaster, W.R., Forney, J.D., 2006. Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in *Leishmania mexicana*. *Mol. Biochem. Parasitol.* 146, 198–218.
- Hudman, D.A., Sargentini, N.J., 2013. Resazurin-based assay for screening bacteria for radiation sensitivity. *SpringerPlus* 2, 55.
- Iyer, J.P., Kaprakkaden, A., Choudhary, M.L., Shaha, C., 2008. Crucial role of cytosolic trypanodioxin peroxidase in *Leishmania donovani* survival, drug response and virulence. *Mol. Microbiol.* 68, 372–391.

- Kamhawi, S., 2006. Phlebotomine sand flies and Leishmania parasites: friends or foes? *Trends Parasitol.* 22, 439–445.
- Kiderlen, A.F., Kaye, P.M., 1990. A modified colorimetric assay of macrophage activation for intracellular cytotoxicity against Leishmania parasites. *J. Immunol. Methods* 127, 11–18.
- Kucab, J.E., Lee, C., Chen, C.S., Zhu, J., Gilks, C.B., Cheang, M., Huntsman, D., Yorida, E., Emerman, J., Pollak, M., Dunn, S.E., 2005. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. *Breast Cancer Res.* 7, R796–R807.
- Kulshrestha, A., Bhandari, V., Mukhopadhyay, R., Ramesh, V., Sundar, S., Maes, L., Dujardin, J.C., Roy, S., Salotra, P., 2013. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. *Parasitol. Res.* 112, 825–828.
- Mandal, S., Maharjan, M., Ganguly, S., Chatterjee, M., Singh, S., Buckner, F.S., Madhubala, R., 2009. High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay. *Indian J. Exp. Biol.* 47, 475–479.
- McNicholl, B.P., McGrath, J.W., Quinn, J.P., 2007. Development and application of a resazurin-based biomass activity test for activated sludge plant management. *Water Res.* 41, 127–133.
- Mikus, J., Steverding, D., 2000. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. *Parasitol. Int.* 48, 265–269.
- Mishra, J., Singh, S., 2013. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death. *Exp. Parasitol.* 135, 397–406.
- Murray, H.W., Brooks, E.B., DeVecchio, J.L., Heinzel, F.P., 2003. Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. *Antimicrob. Agents Chemother.* 47, 2513–2517.
- Musa, A., Khalil, E., Hailu, A., Olobo, J., Balasegaram, M., Omollo, R., Edwards, T., Rashid, J., Mbui, J., Musa, B., Abuzaid, A.A., Ahmed, O., Fadlalla, A., El-Hassan, A., Mueller, M., Mucece, G., Njoroge, S., Manduku, V., Mutuma, G., Apadet, L., Lodenyo, H., Mutea, D., Kirigi, G., Yifru, S., Mengistu, G., Hurissa, Z., Hailu, W., Weldegebreal, T., Tafes, H., Mekonnen, Y., Makonnen, E., Ndegwa, S., Sagaki, P., Kimutai, R., Kesusu, J., Owiti, R., Ellis, S., Wasunna, M., 2012. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. *PLoS Neglected Trop. Dis.* 6, e1674.
- Neal, R.A., Croft, S.L., 1984. An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. *J. Antimicrob. Chemother.* 14, 463–475.
- Neves, B.M., Silvestre, R., Resende, M., Ouaisi, A., Cunha, J., Tavares, J., Loureiro, I., Santarem, N., Silva, A.M., Lopes, M.C., Cruz, M.T., Cordeiro da Silva, A., 2010. Activation of phosphatidylinositol 3-kinase/Akt and impairment of nuclear factor-kappaB: molecular mechanisms behind the arrested maturation/activation state of Leishmania infantum-infected dendritic cells. *Am. J. Pathol.* 177, 2898–2911.
- O'Brien, J., Wilson, I., Orton, T., Pognan, F., 2000. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. *Eur. J. Biochem.* 267, 5421–5426.
- Paape, D., Bell, A.S., Heal, W.P., Hutton, J.A., Leatherbarrow, R.J., Tate, E.W., Smith, D.F., 2014. Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes. *PLoS Neglected Trop. Dis.* 8, e3363.
- Palatnik-de-Sousa, C.B., 2008. Vaccines for leishmaniasis in the fore coming 25 years. *Vaccine* 26, 1709–1724.
- Pan, L., Lezama-Davila, C.M., Isaac-Marquez, A.P., Calomeni, E.P., Fuchs, J.R., Satoskar, A.R., Kinghorn, A.D., 2012. Sterols with antileishmanial activity isolated from the roots of Pentelinon andrieuxii. *Phytochemistry* 82, 128–135.
- Perez-Victoria, F.J., Sanchez-Canete, M.P., Seifert, K., Croft, S.L., Sundar, S., Castanys, S., Gamarro, F., 2006. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. *Drug Resist. Updates* 9, 26–39.
- Pescher, P., Blisnick, T., Bastin, P., Spath, G.F., 2011. Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation. *Cell Microbiol.* 13, 978–991.
- Purkait, B., Kumar, A., Nandi, N., Sardar, A.H., Das, S., Kumar, S., Pandey, K., Ravidas, V., Kumar, M., De, T., Singh, D., Das, P., 2012. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. *Antimicrob. Agents Chemother.* 56, 1031–1041.
- Rijal, S., Chappuis, F., Singh, R., Bovier, P.A., Acharya, P., Karki, B.M., Das, M.L., Desjeux, P., Loutan, L., Koirala, S., 2003. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. *Trans. R. Soc. Trop. Med. Hyg.* 97, 350–354.
- Ruhland, A., Leal, N., Kima, P.E., 2007. Leishmania promastigotes activate PI3K/Akt signalling to confer host cell resistance to apoptosis. *Cell Microbiol.* 9, 84–96.
- Sarker, S.D., Nahar, L., Kumarasamy, Y., 2007. Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicals. *Methods* 42, 321–324.
- Seifert, K., Croft, S.L., 2006. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. *Antimicrob. Agents Chemother.* 50, 73–79.
- Seifert, K., Perez-Victoria, F.J., Stettler, M., Sanchez-Canete, M.P., Castanys, S., Gamarro, F., Croft, S.L., 2007. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. *Int. J. Antimicrob. Agents* 30, 229–235.
- Sereno, D., Cordeiro da Silva, A., Mathieu-Daude, F., Ouaisi, A., 2007. Advances and perspectives in Leishmania cell based drug-screening procedures. *Parasitol. Int.* 56, 3–7.
- Sereno, D., Lemesre, J.L., 1997. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. *Antimicrob. Agents Chemother.* 41, 972–976.
- Shahangian, S., Ash, K.O., Rollins, D.E., 1984. An enzymatic method for the analysis of formate in human plasma. *J. Anal. Toxicol.* 8, 273–276.
- Squires, K.E., Rosenkaimer, F., Sherwood, J.A., Forni, A.L., Were, J.B., Murray, H.W., 1993. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. *Am. J. Trop. Med. Hyg.* 48, 666–669.
- Sundar, S., Chakravarty, J., 2010. Liposomal amphotericin B and leishmaniasis: dose and response. *J. Glob. Infect. Dis.* 2, 159–166.
- Sundar, S., Chakravarty, J., 2013. Leishmaniasis: an update of current pharmacotherapy. *Expert Opin. Pharmacother.* 14, 53–63.
- Sundar, S., Rai, M., Chakravarty, J., Agarwal, D., Agrawal, N., Vaillant, M., Oliario, P., Murray, H.W., 2008. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. *Clin. Infect. Dis.* 47, 1000–1006.
- Sundar, S., Singh, V.P., Sharma, S., Makharia, M.K., Murray, H.W., 1997. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. *J. Infect. Dis.* 176, 1117–1119.
- Urbina, J.A., Cohen, B.E., Perozo, E., Cornivelli, L., 1987. Spin-labeled amphotericin B: synthesis, characterization, biological and spectroscopic properties. *Biochim. Biophys. Acta* 897, 467–473.
- Wadhwa, P., Maiti, M., Agarwal, R., Kamat, V., Martin, S., Saha, B., 2009. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. *J. Immunol.* 182, 7146–7154.
- Wang, Z.E., Reiner, S.L., Zheng, S., Dalton, D.K., Locksley, R.M., 1994. CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. *J. Exp. Med.* 179, 1367–1371.
- Weischenfeldt, J., Porse, B., 2008. Bone marrow-derived macrophages (BMM): isolation and applications. *CSH Protoc* 3 2008:pdb.prot5080.
- World Health Organization, 2018. Leishmaniasis Fact Sheet.
- Zhou, P., Li, Y., Li, B., Zhang, M., Xu, C., Liu, F., Bian, L., Liu, Y., Yao, Y., Li, D., 2018. Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma. *Cell Cycle* 17, 997–1006.
- Zulfikar, B., Shelper, T.B., Avery, V.M., 2017. Leishmaniasis drug discovery: recent progress and challenges in assay development. *Drug Discov. Today* 22, 1516–1531.